Precipio Diagnostics Selects and Implements NovoPath APLIS for Its Complex Hematology-Oncology Testing - WALB.com, Albany News, Weather, Sports

Precipio Diagnostics Selects and Implements NovoPath APLIS for Its Complex Hematology-Oncology Testing

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

Precipio Diagnostics has selected NovoPath anatomic pathology laboratory information system for the management and communication of data to offsite pathologists.

Princeton, NJ (PRWEB) June 27, 2014

Precipio Diagnostics, a hematology-oncology lab, has selected NovoPath anatomic pathology laboratory information system (APLIS) for the management and communication of data to offsite pathologists. Pioneering an innovative laboratory business model, Precipio utilizes remote pathologists at renowned academic institutions to provide high-quality, specialized readings with fast turnaround time.

We selected NovoPath because its sophisticated technology can handle extremely complex hematology-oncology exams, says Ilan Danieli, CEO of the innovative cancer diagnostics lab. Unlike most testing, our specialized exams involve data from a broad range of equipment and must be presented in exactly the appropriate way to both the pathologists interpreting the exams and the referring physicians reading reports. Very few LIS solutions are equipped to handle this level of complexity.

Based on the experience with its initial LIS solution, Precipio specifically sought out a system that was easy-to-use, fast, affordable and customizable, in addition to one that was capable of handling its complex data demands. Our busy pathologists, our customers, require a high level of data organization, and our prior system really fell short, says Danieli.

Danieli notes that Precipios business model requires a unique workflow that the LIS must also accommodate. Patient samples are sent to Precipios lab, which handles the technical component (TC). There, samples are analyzed using all required equipment, and results flow into the NovoPath LIS. The academic pathologists log into the system remotely from their desktops, open a case, review the components and enter their diagnosis. Actual samples are sent to the pathologists by courier, if needed. Precipios lab then outputs the report.

We compared many solutions on the market, and NovoPath was clearly the superior choice, meeting all our criteria, Danieli notes. Our pathologists are extremely pleased with the system and our reports are now well-formatted to meet our needs. The set-up and go live proceeded smoothly. NovoPath LIS has made a clear difference in our business.

We are pleased to provide Precipio with the technology it needs to succeed with its unique business model, comments Rick Callahan, NovoPaths vice president of sales and marketing. Precipios testing menu requires a range of innovative LIS capabilities to support both complexity and productivity. Its choice of NovoPath testifies to the sophistication and flexibility of our solution. We are proud to be a part of Precipios success story.

About NovoPath

NovoPath, Inc. develops and markets software solutions for the Anatomic Pathology Laboratory market segment that includes local, regional, national, and in-house laboratories as well as community and university teaching hospitals and medical centers. Since the release of its flagship product in 1999, NovoPath, Inc. has focused exclusively on Anatomic Pathology. NovoPath's mission is to provide unique and unparalleled solutions and services to all aspects of the Anatomic Pathology sector in a way that improves workflow, reduces the probability of human error, ensures results accuracy for greater patient safety, protects patient confidentiality, and above all, produces more precise and informative diagnostic outcomes. More information is available at http://www.NovoPath.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/06/prweb11977785.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.